Longeveron Inc
LGVN1.720USD
+0.085+5.20%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
25.73MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Longeveron Inc Unternehmen
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
Unternehmensinformationen
BörsenkürzelLGVN
Name des UnternehmensLongeveron Inc
IPO-datumFeb 12, 2021
CEOMr. Wa'el Hashad
Anzahl der mitarbeiter25
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 12
Addresse1951 NW 7th Ave
StadtMIAMI
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33136
Telefon13053027158
Websitehttps://www.longeveron.com/
BörsenkürzelLGVN
IPO-datumFeb 12, 2021
CEOMr. Wa'el Hashad
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Chairman of the Board, Co-Founder, Chief Science Officer
Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.53K
+163.15%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Ms. Ursula Ungaro
Ms. Ursula Ungaro
Independent Director
Independent Director
35.55K
+91.64%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
29.59K
+135.01%
Mr. Richard N. Kender
Mr. Richard N. Kender
Independent Director
Independent Director
22.33K
+318.71%
Mr. Roger Joseph Hajjar
Mr. Roger Joseph Hajjar
Independent Director
Independent Director
21.00K
+425.00%
Ms. Neha Motwani
Ms. Neha Motwani
Independent Director
Independent Director
21.00K
+425.00%
Mr. Rock Soffer
Mr. Rock Soffer
Director
Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Joshua M. Hare, M.D.
Dr. Joshua M. Hare, M.D.
Chairman of the Board, Co-Founder, Chief Science Officer
Chairman of the Board, Co-Founder, Chief Science Officer
253.07K
-2.03%
Ms. Lisa Locklear
Ms. Lisa Locklear
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
152.53K
+163.15%
Dr. Nataliya Agafonova, M.D.
Dr. Nataliya Agafonova, M.D.
Chief Medical Officer
Chief Medical Officer
152.03K
+164.57%
Mr. Devin Blass
Mr. Devin Blass
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
Chief Technology Officer, Senior Vice President - Chemistry, Manufacturing, and Controls
110.15K
+763.93%
Ms. Ursula Ungaro
Ms. Ursula Ungaro
Independent Director
Independent Director
35.55K
+91.64%
Mr. Khoso Baluch
Mr. Khoso Baluch
Independent Director
Independent Director
29.59K
+135.01%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Clinical trial revenue
259.00K
67.98%
Contract manufacturing lease revenue
116.00K
30.45%
Contract manufacturing
6.00K
1.57%
Aktionärsstatistik
Aktualisiert: Fri, Aug 1
Aktualisiert: Fri, Aug 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
5.00%
Lehr (Paul T)
2.44%
Hashad (Mohamed Wa'el Ahmed)
2.30%
Hare (Joshua M)
1.87%
Soffer (Rock J)
1.33%
Other
87.06%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
5.00%
Lehr (Paul T)
2.44%
Hashad (Mohamed Wa'el Ahmed)
2.30%
Hare (Joshua M)
1.87%
Soffer (Rock J)
1.33%
Other
87.06%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
12.30%
Hedge Fund
5.00%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.49%
Research Firm
0.11%
Other
78.93%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
73
2.17M
16.04%
+290.03K
2025Q1
73
2.14M
15.82%
-119.71K
2024Q4
73
2.53M
18.80%
+652.31K
2024Q3
67
2.33M
17.58%
+1.38M
2024Q2
67
924.88K
16.16%
+194.99K
2024Q1
64
168.05K
15.95%
-258.83K
2023Q4
68
363.47K
37.19%
+110.22K
2023Q3
73
198.13K
31.46%
-72.89K
2023Q2
70
193.49K
31.19%
-39.22K
2023Q1
64
155.94K
27.45%
-36.93K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
676.23K
5%
+676.23K
--
Sep 30, 2024
Lehr (Paul T)
229.86K
1.7%
+98.89K
+75.50%
Jun 23, 2025
Hashad (Mohamed Wa'el Ahmed)
144.05K
1.06%
-10.99K
-7.09%
Apr 21, 2025
Hare (Joshua M)
253.07K
1.87%
-5.25K
-2.03%
May 16, 2025
Soffer (Rock J)
162.52K
1.2%
-23.00K
-12.40%
May 30, 2025
Locklear (Lisa)
57.96K
0.43%
-6.21K
-9.68%
Apr 21, 2025
Agafonova (Nataliya)
57.46K
0.42%
-7.56K
-11.63%
Apr 21, 2025
The Vanguard Group, Inc.
144.27K
1.07%
--
--
Mar 31, 2025
Geode Capital Management, L.L.C.
140.73K
1.04%
+7.13K
+5.33%
Mar 31, 2025
Blass (Devin)
12.75K
0.09%
+12.75K
--
Apr 21, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Datum
Art
Verhältnis
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
Mar 19, 2024
Merger
10<1
